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Abstract
Background: Necrotizing pancreatitis is a challenging condition that requires surgical treatment commonly and
is associated with substantial morbidity and mortality. Over the past decade, new definitions have been de-
veloped for standardization of severity of acute and necrotizing pancreatitis, and new management techniques
have emerged based on prospective, randomized clinical trials.
Methods: Review of English-language literature.
Results: A new international classification of acute pancreatitis has been developed by PANCREA (Pancreatitis
Across Nations Clinical Research and Education Alliance) to replace the Atlanta Classification. It is based on
the actual local (whether pancreatic necrosis is present or not, whether it is sterile or infected) and systemic
determinants (whether organ failure is present or not, whether it is transient or persistent) of severity. Early
management requires goal-directed fluid resuscitation (with avoidance of over-resuscitation and abdominal
compartment syndrome), assessment of severity of pancreatitis, diagnostic computed tomography (CT) imaging
to assess for necrotizing pancreatitis, consideration of endoscopic retrograde cholangiopancreatography (ERCP)
for biliary pancreatitis and early enteral nutrition support. Antibiotic prophylaxis is not recommended. Ther-
apeutic antibiotics are required for treatment of documented infected pancreatic necrosis. The initial treatment
of infected pancreatic necrosis is percutaneous catheter or endoscopic (transgastric/transduodenal) drainage
with a second drain placement as required. Lack of clinical improvement after these initial procedures warrants
consideration of minimally invasive techniques for pancreatic necrosectomy including video-assisted retro-
peritoneal debridement (VARD), minimally invasive retroperitoneal pancreatectomy (MIRP), or transluminal
direct endoscopic necrosectomy (DEN). Open necrosectomy is associated with substantial morbidity, but to
date no randomized trial has documented superiority of either minimally invasive or open surgical technique.
Additional trials are underway to address this.
Conclusions: Severe acute and necrotizing pancreatitis requires a multi-disciplinary treatment strategy that
must be individualized for each patient. Optimal treatment of necrotizing pancreatitis now requires a staged,
multi-disciplinary, minimally invasive ‘‘step-up’’ approach that includes a team of interventional radiologists,
therapeutic endoscopists, and surgeons.
Necrotizing pancreatitis develops in 15% of patientswith severe acute pancreatitis with high morbidity and
mortality. Necrotizing pancreatitis is of great importance to
surgeons, because medical management alone does not re-
duce mortality. A new international classification of acute
pancreatitis has been developed by PANCREA (Pancreatitis
Across Nations Clinical Research and Education Alliance) to
replace the Atlanta Classification, based on the actual local
(whether pancreatic necrosis is present or not, whether it is
sterile or infected) and systemic determinants (whether organ
failure is present or not, whether it is transient or persistent)
of severity.
Substantial changes in the management of necrotizing
pancreatitis have emerged in the last decade. Non-operative
management is recommended for sterile pancreatic necrosis.
Antibiotic prophylaxis is not indicated in the initial man-
agement of pancreatic necrosis. Antimicrobial management
is indicated for the treatment of infected pancreatic necrosis.
Division of Acute Care Surgery [Trauma, Burn, Surgical Critical Care, Emergency Surgery], Department of Surgery, University of
Michigan Medical Center, Ann Arbor, Michigan.
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Randomized trials confirm that treatment with open necro-
sectomy results in greater morbidity than conservative sur-
gical approaches. Percutaneous drainage is now the preferred
initial technique for treatment of infected pancreatic necrosis.
Both endoscopic transluminal drainage and minimally in-
vasive necrosectomy have emerged as secondary techniques
for treating infected pancreatic necrosis. Optimal treatment
of necrotizing pancreatitis now requires a staged, multi-
disciplinary, minimally invasive ‘‘step-up’’ approach which
includes a team of interventional radiologists, therapeutic
endoscopists, and surgeons. In this comprehensive review,
we provide evidence-based treatment recommendations for
necrotizing pancreatitis management and highlight a clinical
case to illustrate this treatment algorithm.
Clinical Case
A 38-year-old female presented to an outside hospital with
acute onset of abdominal pain, anorexia, nausea, and vo-
miting 9 d after a 2-d hospital stay for gallstone pancreatitis.
During her previous hospitalization she underwent endo-
scopic retrograde cholangiopancreatography (ERCP) for
choledocholithiasis and was discharged home with a plan for
delayed cholecystectomy. Upon arrival to the emergency
department, a non-contrast abdominal computed tomography
(CT) scan demonstrated a pancreatic phlegmon with retro-
peritoneal air, concerning for infected necrotizing pancrea-
titis and possible duodenal perforation. Given these findings,
she was transferred to the University of Michigan Medical
Center for further management.
The patient’s past medical history was notable for hyper-
tension, hyperlipidemia, and recent supraventricular tachycardia.
On initial physical examination she was afebrile and found
to have diffuse abdominal tenderness without evidence
of peritonitis. A pancreatic protocol intravenous con-
trast abdominal CT scan demonstrated extensive pancre-
atic necrosis, with a large pancreatic abscess (Fig. 1).
Empiric, broad-spectrum antibiotic therapy (meropenem)
was initiated.
Considering her clinical status, vital signs, physical ex-
amination, and laboratory studies, the patient was managed
with percutaneous drainage in an attempt to avoid the mor-
bidity associated with early necrosectomy. Percutaneous
drain placement by interventional radiology was performed
without complication. Cultures of the pancreatic abscess
grew multiple organisms including Enterococcus sp., Kleb-
siella pneumoniae, and Pantoea sp. for which a 3-wk course
of intravenous piperacillin-tazobactam was initiated.
During the course of her hospitalization, a CT angiogram
demonstrated a small splenic artery aneurysm. She under-
went celiac, splenic, common hepatic, gastroduodenal artery,
and superior mesenteric artery arteriography with emboli-
zation of the aneurysm at the splenic hilum. She was dis-
charged home with continued antibiotic therapy and drain
care. On outpatient follow-up the patient presented without
complaints. Repeat CT scan imaging 4 wks later confirmed
complete resolution of infected pancreatic necrosis (Fig. 2)
and the percutaneous drainage catheter was removed. She
underwent uncomplicated laparoscopic cholecystectomy
4 wks later. Final pathology showed evidence of cholelithi-
asis and lymphocytic cholecystitis. This case illustrates the
efficacy of percutaneous drainage for treatment of infected
pancreatic necrosis, even in a patient with extensive peri-
pancreatic infected necrosis.
FIG. 1. Admission computed tomography (CT) scan of the abdomen and pelvis with oral and intravenous contrast. No
normal pancreatic tissue is identified. There is extensive pancreatic necrosis with large collections of fluid and gas
throughout the pancreatic bed, extending caudally in the retroperitoneum, left greater than right. These collections show
broad contact with the descending colon and there is adjacent mild thickening of the wall of the descending colon.
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Diagnosis
Presentation
Acute pancreatitis most often presents as the sudden onset
of upper abdominal or epigastric pain, many times radiating
to the back. The pain may be accompanied by nausea, vo-
miting, fever, or elevated white blood cell count [1–3]. More
severe cases can present with manifestations of respiratory
distress and organ failure, as well as shock. The differential
diagnosis for acute pancreatitis includes acute coronary syn-
drome, acute cholecystitis, perforated gastroduodenal ulcer,
mesenteric ischemia, bowel obstruction, and bowel perforation.
Physical examination may be largely unremarkable with
only minimal epigastric tenderness in patients with mild
disease. More severe illnesses may present with diffuse ab-
dominal tenderness, distention from ileus, and signs of sys-
temic inflammation including tachycardia, tachypnea, and
hypotension. Ecchymosis within the umbilical region (Cullen
sign) or the flank (Grey-Turner sign) although non-specific,
may represent retroperitoneal hemorrhage associated with
severe necrotizing pancreatitis [4]. Other signs such as icterus
and jaundice, hepatomegaly, or xanthomas or other skin le-
sions, may help aide in identifying the underlying etiology.
Diagnostic assays
Several key diagnostic assays assist in the differentiation
of acute pancreatitis from the disease processes mentioned
previously. Serum amylase or lipase concentrations greater
than three times the upper limit of normal, especially in se-
vere abdominal pain, are suggestive of acute pancreatitis.
Although both enzymes can be measured readily, lipase is as
sensitive as, and more specific than, amylase [5]. Further-
more, amylase concentrations tend to decrease more quickly
and thus a patient with any delay in presentation or diagnosis
may be out of the diagnostic window [6].
Markers suggestive of increased trypsinogen activation
(trypsinogen activation peptide, trypsinogen-2) are less sen-
sitive in acute pancreatitis but may be helpful in confirming
the diagnosis. A 2001 report on serum markers to address the
severity of acute pancreatitis noted that procalcitonin con-
centrations are elevated in patients with acute infected pan-
creatic necrosis. Furthermore, a rapid test strip test for
procalcitonin (PCT-Q, B.R.A.H.M.S., Thermo Fisher Scien-
tific, Waltham, MA) was described as an effective screening
test (sensitivity 92%–95%, negative predictive value 97%)
for detecting severe acute pancreatitis at 24 h post-admission,
compared with other commonly used predictors of severity
(C-reactive protein concentrations, Ranson scores, and Acute
Physiology and Chronic Health Evaluation [APACHE] II
scores) [7].
Diagnostic imaging
Contrast-enhanced computed tomography (CECT) is a key
tool in differentiating severe acute pancreatitis from other
sources of upper abdominal pain, and should be performed
within 72 h of symptom onset [8]. Contrast-enhanced com-
puted tomography is also the gold standard for diagnosis of
pancreatic necrosis in acute pancreatitis and a new, more
standardized definition for radiologic terminology is being
sought to classify findings better [9]. Pancreatic necrosis
appears as areas of low- to no-enhancement on CECT due to
disruptions in the pancreatic microcirculation. If the pancreas
is greater than 30% necrotic, the accuracy of CECT in di-
agnosing necrotizing pancreatitis reaches 90%. The amount
of necrotic glandular tissue by CECT is also a predictive
factor for the severity of the disease and is stratified into three
categories: less than 30%, 30%–50%, and greater than 50%
necrosis. Infection of the necrotic tissue is diagnosed via CT
or ultrasound-guided, fine-needle aspiration of the tissue,
followed by culture and gram stain. Of the available options,
CT-guided aspiration is preferred because it has a higher
sensitivity and specificity versus other modalities.
Evolving Definitions
1992 Atlanta Classification
Severe acute pancreatitis was described initially in 1992 on
the basis of the Atlanta Classification [10]. It defined acute
pancreatitis as ‘‘an acute inflammatory process of the pan-
creas with variable involvement of other regional tissues or
remote organ systems.’’ Furthermore, severe acute pancrea-
titis was defined as ‘‘acute pancreatitis associated with organ
failure or local complications such as necrosis, abscess or
pseudocyst’’ (Tables 1 and 2). Although non-specific, this
represented the first true attempt at creating a standardized
definition of the pancreatitis disease process.
FIG. 2. Repeat computed tomography (CT) scan (4 wks after admission) of the abdomen and pelvis with oral and
intravenous contrast. After radiologic image-guided percutaneous drain placement at outpatient follow-up: Near resolution
of the previously noted collections with a marked improvement in inflammation.
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2008 Acute Pancreatitis Working Group
A 2008 evaluation of the Atlanta Classification suggested
that the definitions outlined in 1992 were used infrequently,
inconsistently, and inappropriately [11]. Furthermore, a bet-
ter understanding of the disease process, enhanced imaging
modalities, and new intervention strategies had all been de-
veloped since the Atlanta Classification’s inception. The
Atlanta Classification has several limitations. It does not
account for the length of time since inception of the disease, it
Table 1. Severity: Comparison between the Atlanta and the 2008 Pancreatitis
Working Group Definitions
Summary of the Atlanta Classification
Summary of Acute Pancreatitis
Working Group 2008
Acute pancreatitis An acute inflammatory process of the
pancreas with variable involvement
of other regional tissues or remote
organ systems
Associated with raised pancreatic
enzymes in blood or urine.
Two of the following features:
 Abdominal pain suggestive strongly
of acute pancreatitis
 Serum amylase or lipase activity
at least 3 times greater than the upper
limit of normal
 Characteristic findings of acute pancreatitis
on transabdominal ultrasonography or
on CECT
Onset of acute pancreatitis defined as time
of onset of abdominal pain
Severity
Mild acute
pancreatitis
Associated with minimal organ
dysfunction and an uneventful
recover; lacks the features of
severe acute pancreatitis, usually
normal enhancement of pancreatic
parenchyma on contrast-enhanced
computed tomography
Severe acute
pancreatitis
Associated with organ failure and/or
local complications such as necrosis,
abscess, or pseudocyst
First 48 h:
Presence of SIRS or organ failure
Over First Week:
Persistence of organ failure that exceeds
48 hours
Predicted severity Ranson score ‡ 3 or APACHE II
score ‡ 8
Age, BMI, hematocrit, APACHE II,
serum C-reactive protein
Interstitial
Pancreatitis
CECT demonstration of diffuse or
localized enlargement of pancreatic
parenchyma with associated fluid
collections lacking solid components
Organ failure and
systemic
complications
Shock: Systolic blood pressure< 90mm Hg
Pulmonary insufficiency: PaO2 £ 60mm Hg
Renal failure: creatinine ‡ 177mcmol/L
or £ 1.92mg/dL after rehydration
Gastrointestinal bleeding: 500mL in 24 h
Disseminated intravascular coagulation:
platelets £ 100,000/mm3, fibrinogen
< 1.0mg/L, and fibrin-split products
> 80mg/L
Severe metabolic disturbances: calcium
£ 1.87 mmol/L or£ 7.5mg/dL
Cardiac, respiratory, and/or renal function
achieve a score of ‡ 2 on the Marshall
Scoring System:
 Cardiovascular (systolic blood pressure):
< 90mm Hg and not fluid responsive
 Respiratory (PaO2/FiO2): £ 300
 Renal (serum creatinine): renal:
‡ 171 mcmol/L, ‡ 1.9mg/dL
SIRS Two or more for > 48 h:
 pulse > 90 bpm
 rectal temperature < 36C or > 38C
 WBC < 4,000 or > 12,00 per mm3
 Respiratory rate > 20/min or
PCO2 < 32mm Hg
Adapted from: Bradley EL 3rd. A clinically based classification system for acute pancreatitis. Summary of the International Symposium
on Acute Pancreatitis, Atlanta, GA, September 11–13, 1992. Arch Surg. 1993;128:586–589 and Bollen TL, van Santvoort HC, Besselink
MG, et al. The Atlanta Classification of AP revisited. Br J Surg 2008;95:6–21.
CECT = contrast-enhanced computed tomography; SIRS = systemic inflammatory response syndrome; BMI = body mass index; WBC =
white blood cell count.
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Table 2. Local Complications: Comparison between the Atlanta and the 2008 Pancreatitis
Working Group Definitions
Summary of the Atlanta Classification
Summary of Acute Pancreatitis
Working Group 2008
Acute pancreatitis An acute inflammatory process of the pancreas
with variable involvement of other regional
tissues or remote organ systems
Associated with raised pancreatic enzymes in
blood and/or urine.
Two of the following features:
 Abdominal pain suggestive
strongly of acute pancreatitis
 Serum amylase or lipase activity
at least 3 times greater than the
upper limit of normal
 Characteristic findings of acute
pancreatitis on transabdominal
ultrasonography or on CECT
Onset of acute pancreatitis defined
as time of onset of abdominal pain
Local Complications
Acute fluid
collections
Occur early in the course of acute pancreatitis,
are located in or near the pancreas and
always lack a wall of granulation of fibrous
tissue. In about half of patients, spontaneous
regression occurs. In the other half, an acute
fluid collection develops into a pancreatic
abscess or pseudocyst
Pancreatic
necrosis
Diffuse or focal area(s) of non-viable pancreatic
parenchyma, typically associated with
peri-pancreatic fat necrosis.
Areas of pancreatic parenchymal
non-enhancement on CECT.
Non-enhanced pancreatic parenchyma > 3 cm
or involving more than 30% of the pancreas.
Quantified into 3 categories:
< 30%, 30%–50%, > 50%.
APFC Fluid collections in patients with
IEP with no solid components
and in the absence of necrosis.
Most commonly sterile but may
be infected
Infection Evidence of infection based on
guided fine needle aspiration
with positive Gram stain and
culture.
Can be assumed with presence of
extraluminal gas.
PNPFC Fluid collections from patients
with acute necrotizing pancreatitis
that contain both fluid and
necrotic debris.
Matures to become WOPN
characterized by a thickened wall
without epithelial lining
Acute
pseudocyst
Collection of pancreatic juice enclosed by a wall
of fibrous or granulation tissue, which arises as
a result of acute pancreatitis, pancreatic trauma,
or chronic pancreatitis, occurring at least 4 wks
after onset of symptoms, is round or ovoid and
most often sterile; when pus is present, lesion
is termed a pancreatic abscess.
Defined after more than 4 wks after
onset as well-circumscribed, round,
or oval, homogeneous fluid collection
surrounded by a well-defined wall
with no associated tissue necrosis
within fluid collection.
May be sterile or infected. Infected
pseudocyst contains purulent
liquid without necrosis.
Pancreatic
abscess
Circumscribed, intra-abdominal collection of puss
usually in proximity to the pancreas, containing
little or no pancreatic necrosis, which arises as a
consequence of acute pancreatitis or pancreatic
trauma. Often 4 wks or more after onset
Pancreatic abscess and infected pancreatic necrosis
differ in clinical expression and extent of
associated necrosis.
CECT = contrast-enhanced computed tomography; APFC= acute peri-pancreatic fluid collections; PNPFC = post-necrotic pancreatic/
peri-pancreatic fluid collections; WOPN =walled-off pancreatic necrosis.
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fails to distinguish between peri-pancreatic and pancreatic
parenchymal necrosis, it relies too heavily on only modestly
accurate severity predictors on an individual patient level,
and it fails to establish exact radiologic criteria regarding
local complications. The 2008 Acute Pancreatitis Working
Group wanted to update, clarify, and improve clinical as-
sessment, and standardize the definitions described by the
Atlanta Classification. These distinctions are summarized in
Tables 1 and 2.
2011 World Congress
Although the 2008 Atlanta Classification represents an
improvement over the 1992 classification, in 2011 the World
Congress of the International Association of Pancreatology
suggested an expansion of the classification system to in-
corporate better the risks associated with multiple organ
dysfunction syndrome. They argued that a binary classifica-
tion system did not stratify patients sufficiently with respect
to their mortality risk.
A new international classification of severity of acute
pancreatitis based on the actual local (whether pancreatic
necrosis is present or not, whether it is sterile or infected)
and systemic determinants (whether organ failure is present
or not, whether it is transient or persistent) of severity (Table 3)
was developed by PANCREA (Pancreatitis Across Nations
Clinical Research and Education Alliance) to replace the
Atlanta Classification. The new system uses local and sys-
temic determinants of severity to categorize acute pan-
creatitis into four subcategories: mild, moderate, severe,
and critical (Table 4) [12]. It is hoped that this new defini-
tion and classification system will standardize patient se-
verity for all future clinical trials of acute and necrotizing
pancreatitis.
Epidemiology
Acute pancreatitis is a common and often self-limiting
inflammatory process involving the pancreas and surround-
ing tissues. Although substantial limitations exist in deter-
mining the true incidence, it is believed to be between 4.9 and
35 per 100,000 persons each year [13] with an annual cost of
more than $2 billion [14]. Chronic ethanol abuse and chole-
lithiasis are the two most common etiologies, accounting for
nearly 220,000 hospital admissions annually [15]. Approxi-
mately 15%–20% of these patients progress to severe acute
pancreatitis, a less common self-limiting disease process,
with a mortality rate of 10%–30%.
Severe acute pancreatitis progresses to necrotizing pancre-
atitis in approximately 15% of patients. Infected pancreatic
Table 3. New International Classification of Acute Pancreatitis: Determinants of Severity of Acute
Pancreatitis by the 2011 World Congress of the International Association of Pancreatology
Local determinant:
Peri-/pancreatic necrosis
Systemic determinant:
organ failure
Nonviable tissue located in the pancreas alone, or in the
pancreas and peri-pancreatic tissues, or in peri-pancreatic
tissues alone. It can be solid or semi-solid (partially
liquefied) and is without a radiologically defined wall.
Defined for three organ systems on the bases of
the worst measurement over a 24 h period.
In patients without pre-existing organ
dysfunction, defined as either SOFA score
of 2 or more in the assessed organ system or:
 Cardiovascular: Need for inotropic agent
 Renal: ‡ 171 mcmol/L ( ‡ 2.0mg/dL)
 Respiratory: PaO2 £ 300mm Hg ( £ 40 kPa)
Sterile necrosis No proven infection in necrosis. Transient organ failure Evidence of organ failure
in the same organ system
for less than 48 h.
Infected necrosis At least one is present: Persistent organ failure Evidence of organ failure
in the same organ system
for 48 hours or more.
1. Gas bubbles within peri-/
pancreatic necrosis on CT
2. Positive culture by image-
guided fine-needle aspiration
3. Positive culture obtained
during the first drainage
and/or necrosectomy
SOFA= Sepsis-related Organ Failure Assessment score; CT= computed tomography.
Adapted from: Dellinger EP, Forsmark CE, Layer P, et al; Pancreatitis Across Nations Clinical Research and Education Alliance
(PANCREA). Determinant-based classification of acute pancreatitis severity: An international multidisciplinary consultation. Ann Surg
2012;256:875–880.
Table 4. New International Classification
of Acute Pancreatitis by the 2011 World
Congress of the International Association
of Pancreatology
Mild AP No evidence of necrosis or organ failure
Moderate AP Evidence of sterile necrosis or transient
organ failure
Severe AP Evidence of infected necrosis or persistent
organ failure
Critical AP Evidence of infected necrosis and
persistent organ failure
AP = acute pancreatitis.
Adapted from: Dellinger EP, Forsmark CE, Layer P, et al.
Pancreatitis Across Nations Clinical Research and Education
Alliance (PANCREA). Determinant-based classification of acute
pancreatitis severity: An international multidisciplinary consulta-
tion. Ann Surg 2012;256:875–880.
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necrosis occurs in 30% to 70% of patients with necrotiz-
ing pancreatitis and is associated with a high mortality rate
(19%–24%) compared with sterile necrotizing pancreatitis
(7%–11%). Within all of these categories, multiple organ
dysfunction syndrome is a major prognostic factor for mor-
tality as well as infection [16,17] and early surgical interven-
tion [18]. Long-term outcomes associated with necrotizing
pancreatitis include compromised endocrine and exocrine
function, with the severity of these outcomes related to the
amount of necrotic pancreatic tissue and degree of infection.
Pathophysiology
Activation of zymogens
A cornerstone of the development of acute pancreatitis is
an inciting event that causes abnormal activation or accu-
mulation of trypsinogen. Normally, active trypsin is stored in
acinar vacuoles. In acute pancreatitis these vacuoles become
overwhelmed and eventually rupture, releasing active tryp-
sin. Active trypsin then activates free trypsinogen and other
pancreatic zymogens that are capable of pancreatic tissue
digestion and activation of the complement cascade. These
enzymes can also cause damage to the local microvascula-
ture, resulting in vasoconstriction and decreased oxygen
perfusion that can lead to progressive ischemia [19].
Inflammatory cell response
Cellular injury leads to complement activation and sub-
sequent macrophage and polymorphonuclear leukocyte re-
cruitment. Activation of these cells leads to the release of a
number of mediators that can worsen pancreatic injury by
acting as proinflammatory mediators or by causing further
activation of pancreatic zymogens.
Once a cell is damaged beyond the point of repair, it un-
dergoes either apoptosis or necrosis depending on the envi-
ronment. Apoptosis is a highly structured process of planned
cell death that requires an abundance of energy. Macrophage
recognition of apoptotic cell-associated molecular patterns
(ACAMPs) produces anti-inflammatory effects. Mild forms
of acute pancreatitis tend to be associated with acinar apo-
ptosis, leading to pancreatic atrophy and subsequent resolu-
tion of symptoms. Furthermore, in severe acute pancreatitis,
apoptosis has been found not only within the pancreas itself,
but also in other organs, possibly contributing to the systemic
effects associated with the disease process [20].
Necrosis
Necrosis is less energy-dependent and more chaotic than
apoptosis. Necrotic debris is recognized by macrophages as a
pathogen-associated molecular pattern (PAMP). The inter-
action of PAMPs with macrophage toll-like receptors acti-
vates nuclear factor-kB (NF-kB), an inhibitor of apoptosis as
well as an indirect promoter of necrosis, and an important
transcription factor for multiple proinflammatory mediators.
Animal studies have demonstrated a relationship between
NF-kB and mechanisms of cellular inflammation and apo-
ptosis in acute pancreatitis [21].
Necrotic pancreatic tissue is found in more severe forms of
acute pancreatitis and can lead to complications such as acute
necrotic collection (ANC), walled-off pancreatic necrosis
(WOPN), or pseudocyst formation [22]. Infection of the ne-
crotic tissue most often occurs secondary to a compromise
in the normal gut-pancreas barrier, allowing normal enteric
flora to translocate from the gastrointestinal system into the
pancreas. Infected pancreatic tissue may lead to local or
systemic effects including sepsis and multiple organ dys-
function syndrome.
Management
Antibiotics
Historically, the use of prophylactic antibiotics in sterile
necrotizing pancreatitis has been controversial. Early trials
tested the efficacy of ampicillin, whereas later trials included
antimicrobial agents such as carbapenems, fluoroquinolones,
or cephalosporins. Although initial small studies demon-
strated some benefit [23], this was not confirmed in three
major randomized controlled trials [24–26]. Multiple meta-
analyses confirmed no significant infection reduction or
mortality benefit in patients with pancreatic necrosis with
prophylactic antibiotics [27–29]. Current evidence-based
recommendations do not support the use of prophylactic an-
tibiotics for ANP.
Evidence of infected pancreatic tissue, sepsis, and sys-
temic inflammatory response syndrome (SIRS) are indicators
for therapeutic antimicrobial agent use in acute pancreatitis
[30]. Furthermore, factors such as an elevated lactate dehy-
drogenase cocentrations, low PaO2, higher CT severity index,
and delayed fluid resuscitation have been associated with an
increased risk of infection [31]. Pathogens spread easily from
the non-encapsulated pancreas to other abdominal organs.
Most commonly gram-negative in bacteriology, an increase
in gram-positive organisms, has been noted [32,33]. In sepsis,
early empiric broad-spectrum antibiotics are recommended
to reduce mortality, as inappropriate antimicrobial adminis-
tration results in a five-fold increase in mortality in septic
shock [34]. Broad-spectrum antibiotics should be adjusted
and narrowed based on final culture and susceptibility results.
Failure to do so has resulted in an increased incidence of
multi-drug resistant organisms [35] as well as fungal infec-
tions [36] within the pancreatic tissue. Fine-needle aspiration
(FNA) may be useful in patients with signs of sepsis but
equivocal findings of infected pancreatic necrosis on diag-
nostic imaging and is particularly helpful in pathogen iden-
tification and appropriate de-escalation of antimicrobial
therapy for infected pancreatic necrosis [37].
Resuscitation
Fluid losses are of major concern in acute pancreatitis and
are increasingly important in severe cases. Goal-directed
resuscitation with intravenous fluids is recommended to
correct for potential volume depletion-related complica-
tions with an aim to maintain a heart rate under 100 beats/
min and systolic blood pressure > 90mm Hg [38,39]. After
initial bolus fluid therapy to achieve hemodynamic stability
is completed [28], a continuous infusion should be initiated
at approximately 3mL/kg/h [40]. Fluid rates should then be
titrated and adjusted such that blood urea nitrogen (BUN)
concentrations decrease to less than 22mg/dL or at the very
least begin to decrease [41]. A 2009 retrospective study
suggested that there may be an early therapeutic window
for aggressive fluid resuscitation. Furthermore, substantial
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third-space losses may be associated with increased com-
plications such as worsening necrosis and organ dysfunction
[42].
Given the importance of early, adequate fluid resuscita-
tion, we have developed an online tool to help guide this
initial phase. Termed ‘‘PancMap,’’ this resource provides an
algorithm for establishing the diagnosis and severity of dis-
ease using the Bedside Index for Severity in Acute Pan-
creatitis (BISAP) score (Table 5), as well as calculations of
initial intravenous fluid requirements and end points per goal-
directed resuscitation. The BISAP score was chosen as a
quick, easy method to assess severity of acute pancreatitis;
multiple studies have confirmed that the BISAP predicts se-
verity, death, and organ failure in acute pancreatitis as well as
APACHE II does and better than Ranson criteria, CT severity
index, and other scoring systems [43–45].
Current proposed end points for fluid resuscitation in acute
pancreatitis include hemodynamic stability, urine output
‡ 0.5mL/kg/h2, and a BUN concentration that is decreasing
at 24 h. We have demonstrated that the use of an early, au-
tomated paging alert system and an intuitive Web-based
point-of-care instrument that guides clinicians with early
management of acute pancreatitis was associated with im-
proved early fluid resuscitation and resulted in decreased
length of hospital stay [46].
Appropriate fluid resuscitation is desired, but there is also
risk with over-resuscitation with the potential for develop-
ment of abdominal hypertension and subsequently abdominal
compartment syndrome [47,48]. A recent systematic review
reported that 38% of acute pancreatitis patients developed
abdominal compartment syndrome which was associated
with higher mortality (49% vs. 11% without abdominal
compartment syndrome) [49]. If abdominal compartment
syndrome does develop, decompressive laparotomy may
be required. An ongoing randomized clinical trial aims
to compare percutaneous drainage versus laparotomy for
decompression (DECOMPRESS trial; ClinicalTrials.gov
NCT00793715) [50]. Thus a balance must be reached be-
tween providing sufficient intravascular volume for end
organ perfusion and avoidance of over-resuscitation to pre-
vent these potential complications. The specific type of fluid
(crystalloid or colloid) for optimal resuscitation in acute
pancreatitis is unknown and may be moot as a systematic
review found no significant differences [51].
Nutrition
In patients with mild acute pancreatitis, regular oral intake
may resume with symptom improvement [52] or when pa-
tients are subjectively hungry [53]. By contrast, patients with
moderate or severe pancreatitis may not be able to tolerate
sufficient oral nutrition for a protracted period. Therefore,
after initial resuscitation, early nutritional support should be
provided to patients with an expected period of inadequate
nutrition of at least 5 to 7 d [54].
Although parenteral nutrition was considered historically
the route of choice, current evidence now demonstrates en-
teral nutrition to be superior when able to be tolerated. Sev-
eral studies comparing the two methods of administration
have been undertaken demonstrating improved outcomes
with enteral nutrition for organ dysfunction, infectious
complications [55,56], and mortality [57]. These benefits
were emphasized further on meta-analysis [58,59] and a
Cochrane review [60] demonstrated substantially improved
morbidity and mortality with enteral nutrition. Furthermore,
early initiation of parenteral nutrition (within 48 h) increases
complications versus delayed (after 8 d) in critically ill pa-
tients [61]. Considering the above, parenteral nutrition should
be limited to those patients who are unable to tolerate the
enteral route due to ileus or worsening symptoms, with its
initiation occurring after the initial severe inflammatory re-
sponse [62,63].
In regards to the optimal location to administer enteral
feeding, there is little evidence to differentiate between the
efficacy of gastric versus jejunal enteral nutrition. No sig-
nificant differences in complications of worsening organ
dysfunction or mortality have been found [64,65]. Concerns
for aspiration, worsening of abdominal pain, or diarrhea have
all been raised, yet by meta-analysis were not more common
with gastric feeding [66]. However, in patients with evidence
of gastric outlet obstruction or in those who do not tolerate
gastric feeding there may be benefit from jejunal access for
enteral nutrition delivery. An ongoing multi-center trial
(pancreatitis, very early compared with normal start of en-
teral feeding [PYTHON trial]) is comparing very early na-
sojejunal feeding within 24 h of acute pancreatitis onset to
standard practice (oral nutrition on demand or enteral feeding
after 72 h of acute pancreatitis onset) [67].
Debridement
The question of if and when to pursue surgical intervention
in patients with necrotizing pancreatitis has become defined
increasingly and trends have shifted toward reserving oper-
ative management to specific indications. In patients without
evidence of infection, continued supportive therapy is re-
commended even in the setting of other organ dysfunction
[68]. However, when evidence of infected necrosis is present,
this may necessitate more invasive measures. Numerous
studies support a reduction in morbidity and mortality when
intervention is postponed.Waiting at least two [69] and ideally
4–6 wks, results in less associated complications and death
versus early intervention [70–72]. However, in patients with
worsening septic shock and clinical deterioration, early in-
tervention may be warranted.
Open necrosectomy has been the traditional surgical in-
tervention for infected pancreatic necrosis with the goal of
removing all infected tissue to provide adequate source
Table 5. BISAP Severity Score
for Acute Pancreatitis
BISAP score 2 3 4 5
Mortality 0%–2% 5%–9% 13%–50% 23%–33%
Score‡ 3 predicts severe disease (1 point for each variable within
first 24 h).
Composite score ranges 0–5 and directly correlates with mortality.
BUN> 25mg/dL.
Impaired mental status (any) [disorientation, lethargy, somno-
lence, stupor, coma]
SIRS (Systemic Inflammatory Response Syndrome).
Age> 60 years.
Pleural effusion.
From: Wu BU, Johannes RS, Sun X, et al. The early prediction of
mortality in acute pancreatitis: A large population-based study. Gut
2008;57:1698–1703.
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control of sepsis. It is an effective procedure that is largely
responsible for the decrease in mortality from necrotizing
pancreatitis in the past decades. However, open necro-
sectomy is associated with high morbidity and mortality
(20%) rates, as well as risk of infection spread due to a lack of
intra-abdominal compartmentalization [73]. Other compli-
cations associated with open necrosectomy include fascial
dehiscence, incision complications, hemorrhage, gastroin-
testinal fistula, and incisional hernia.
Minimally invasive techniques have been developed to
replace open necrosectomy for the treatment of infected
pancreatitic necrosis. Percutaneous catheter drainage alone is
an effective alternative to open necrosectomy and is associ-
ated with reduced morbidity and mortality in selected
patients. However, it is a slow process and may be labor-
intensive, may require multiple percutaneous drains, and
frequent lavage and drain exchanges may be required. Al-
though feasible in stable patients in a system with appropriate
resources, this approach may not be adequate for optimal
source control in patients who are critically ill [74]. Trans-
luminal endoscopic drainage is also effective.
Video-assisted retroperitoneal debridement (VARD) or
minimally invasive retroperitoneal pancreatectomy (MIRP)
utilize the tract created by percutaneous drainage catheters as
a guide for placement of a laparoscope into the retro-
peritoneum such that debridement and lavage can be under-
taken under direct visualization [76]. Compared with open
necrosectomy, improvement in morbidity and mortality has
been demonstrated [76–78].
Transluminal direct endoscopic necrosectomy (DEN)
involves placement of an endoscope (most commonly trans-
gastric or transduodenal optimally with endoscopic ultrasound
guidance), followed by transmural puncture with access to the
adjacent peri-pancreatic collections. Subsequently, necrotic
debris can be debrided and removed via numerous endoscopic
techniques. By meta-analysis, the DEN procedure appears to
FIG. 3. Step-up approach to management of infected ancreatic necrosis. Adapted from: Besselink MG, van Santvoort HC,
Nieuwenhuijs VB, et al. Dutch Acute Pancreatitis Study Group. Minimally invasive ‘‘step-up approach’’ versus maximal
necrosectomy in patients with acute necrotizing pancreatitis (PANTER trial): Design and rationale of a randomized
controlled multicenter trial [ISRCTN13975868]. BMC Surg 2006;6:6.
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be well tolerated with a resolution rate of 76% and relatively
low morbidity (30%) and mortality (5%) in a select patient
population [79]. A more recent systematic review confirmed
81% definitive successful treatment, 6% mortality and 36%
morbidity with DEN [80]. Results from a U.S. multi-center
series from six tertiary medical centers documented that suc-
cessful resolution of WOPN was achieved with DEN in 91%
of patients [81]. Best utilized with WOPN and performed by
skilled endoscopists, DEN has been shown to be a viable op-
tion in the treatment of infected necrosis [82].
The ‘‘step-up’’ approach
Combining several of the above techniques, the ‘‘step-up’’
approach to management of infected pancreatic necrosis aims
to utilize the least invasive technique first, with progressive
escalation for treatment failure. Most commonly, percuta-
neous drain placement is the first modality, with some centers
using endoscopic drainage as well. Stemming from the multi-
center randomized controlled PANTER trial, if within 72 h of
drain placement there was no clinical improvement (Fig. 3), a
second drainage procedure was performed. If the patient fails
to improve after the second drain placement, VARD is re-
commended as the next step in management. In the PANTER
trial, fewer than two-thirds of the patients assigned to the
step-up approach required VARD after percutaneous drain-
age failed. Compared with the patients randomized to open
necrosectomy, the mortality rates were similar, however,
those treated with the step-up approach experienced a sig-
nificant reduction in new-onset organ dysfunction (12% vs.
40%, p = 0.002) as well as long-term complications including
the incidence of incisional hernia, new-onset of diabetes, and
need for pancreatic enzyme replacement. A significantly
lower rate of the composite end point of major morbidity
or death was found in the step-up group (40% vs. 69%,
p = 0.006) [83]. When possible, intervention was delayed
4 wks after the onset of symptoms indicative of acute pan-
creatitis. This allowed ample time for potential resolution of
the disease process or for the transformation of solid debris
into liquefactive necrosis that could be managed with per-
cutaneous drainage. The PANTER trial has added additional
evidence to the recommendation that surgical intervention
should be delayed as long as possible while less invasive
medical and radiologic interventions are used [84,85].
The initial PANTER trial compared open necrosectomy,
a therapy with a well-documented high rate of compli-
cations, with the step-up approach. Because a promising
minimally invasive alternative to the step-up approach is
endoscopic transgastric necrosectomy, a randomized con-
trolled trial (PENGUIN, Primary Necrosectomy in Patients
With Infected Necrosis) examined endoscopic transgastric
versus surgical necrosectomy in patients with infected
pancreatic necrosis. Endoscopic transgastric necrosectomy
was associated with a reduced inflammatory response as
measured by serum interleukin (IL)-6 concentration and
reduced composite end point of major complications (new-
onset multiple organ dysfunction syndrome, intra-abdomi-
nal bleeding, enterocutaneous fistula, pancreatic fistula, or
death [20% vs. 80%, p = 0.03]), but the sample size was
small (n = 20) [86].
The endoscopic technique can also be applied in a step-
up manner, consisting of endoscopic transluminal drainage
followed, if necessary, by DEN for treatment of infected
necrotizing pancreatitis. Comparison of the transluminal
endoscopic step-up to the minimally invasive surgical step-
up approach has been achieved with the recent completion
of the TENSION trial. This trial is a randomized controlled
parallel-group superiority multi-center trial that randomly
assigned patients to either endoscopic or surgical step-up,
with the hypothesis that the endoscopic approach would
have a lower primary end point of mortality and major
complication. Publication of results of this trial are still
pending [87].
Optimal Necrotizing Pancreatitis Management: Staged
Minimally Invasive Multidisciplinary Step-Up Approach
Based on the evidence available to date, patients with
necrotizing pancreatitis require an individualized multi-
disciplinary management approach for optimal treatment to
achieve the best outcomes, reduce mortality, and prevent
associated complications. Modern treatments for necrotizing
pancreatitis, debridement, or necrosectomy have evolved into
minimally invasive options (VARD, MIRP or DEN) rather
than open surgical necrosectomy [88]. Current evidence-
based treatment includes an initial step of drainage (either
percutaneous catheter or transluminal endoscopic) and then
frequent re-evaluation of the clinical success of this ap-
proach. Surgical or endoscopic transluminal debridement is
now only required with lack of clinical resolution and is
delayed until necrosis has become ‘‘walled off’’ (WOPN)
[89]. Overall, considering the growing evidence to support
minimally invasive techniques and delaying or even avoiding
major surgical procedures with this algorithm, the step-up
endoscopic and surgical approach is emerging as the standard
of care in the appropriate necrotizing pancreatitis patient.
Both endoscopic transluminal drainage and minimally inva-
sive necrosectomy have emerged as secondary techniques for
treating infected pancreatic necrosis after initial percutaneous
catheter drainage or endoscopic transgastric or transduodenal
drainage. Optimal treatment of necrotizing pancreatitis now
requires a staged multi-disciplinary minimally invasive step-
up approach that includes a team of interventional radiolo-
gists, therapeutic endoscopists, and surgeons.
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